High liposomal doxorubicin tumour tissue distribution, as determined by radiopharmaceutical labelling with 99mTc-LD, is associated with the response and survival of patients with unresectable pleural mesothelioma treated with a combination of liposomal doxorubicin and cisplatin

• Published in: Cancer chemotherapy and pharmacology Vol. 74; no. 1; pp. 211 - 215
• Main Authors: Arrieta, Oscar, Medina, Luis-Alberto, Estrada-Lobato, Enrique, Ramírez-Tirado, Laura-Alejandra, Mendoza-García, Víctor-Osvaldo, de la Garza-Salazar, Jaime
• Format: Journal Article
• Language: English
• Published: Berlin/Heidelberg Springer Berlin Heidelberg 01.07.2014; Springer
• Subjects: Antineoplastic agents; Biological and medical sciences; Cancer Research; Medical sciences; Medicine; Medicine & Public Health; Oncology; Pharmacology. Drug treatments; Pharmacology/Toxicology; Short Communication; Technetium-labelled liposomal doxorubicin; Response rate; Mesothelioma; Chemotherapy; Uptake; Antineoplastic agent; Doxorubicin; Isomerases; Tumor; Radioisotopic product; Pleura; Platinum II Complexes; Human; DNA topoisomerase (ATP-hydrolysing); Drug combination; Enzyme; Enzyme inhibitor; Liposome; Topoisomerase II inhibitor; Survival; Cisplatin; Alkylating agent; Treatment; Distribution; Unresectable; Anthracyclins; Pharmacokinetics
• ISSN: 0344-5704; 1432-0843
• DOI: 10.1007/s00280-014-2477-x

Background There are currently no available biomarkers for advanced pleural mesothelioma that determine which patients could benefit from a specific chemotherapy regimen. Methods Based on the results of a previously published phase II study, we associated the 99m Technetium-labelled liposomal doxorubicin ( 99m Tc-LD) uptake value (75 % cut-off) with the response rate, progression-free survival and overall survival of patients treated with a combination of liposomal doxorubicin and cisplatin. Results Patients with tumours exhibiting increased 99m Tc-LD uptake showed better response rates, progression-free survival and overall survival than those exhibiting lower uptake 73.3 versus 15 % ( p  < 0.001); 6.9 versus 3.2 months ( p  = 0.033) and 23 versus 6.6 months ( p  = 0.001), respectively. Conclusion 99m Tc-DL uptake in tumour tissue could define a set of patients who would benefit from this chemotherapy regimen.